GR3036322T3 - In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene - Google Patents
In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility geneInfo
- Publication number
- GR3036322T3 GR3036322T3 GR20010401173T GR20010401173T GR3036322T3 GR 3036322 T3 GR3036322 T3 GR 3036322T3 GR 20010401173 T GR20010401173 T GR 20010401173T GR 20010401173 T GR20010401173 T GR 20010401173T GR 3036322 T3 GR3036322 T3 GR 3036322T3
- Authority
- GR
- Greece
- Prior art keywords
- ovarian cancer
- breast
- polymorphisms
- susceptibility gene
- cancer susceptibility
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 6
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 6
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 6
- 206010061535 Ovarian neoplasm Diseases 0.000 title abstract 6
- 210000000481 breast Anatomy 0.000 title abstract 6
- 230000035772 mutation Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000001727 in vivo Methods 0.000 title 1
- 102000054765 polymorphisms of proteins Human genes 0.000 title 1
- 108700040618 BRCA1 Genes Proteins 0.000 abstract 2
- 101150072950 BRCA1 gene Proteins 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 206010069754 Acquired gene mutation Diseases 0.000 abstract 1
- 108700028369 Alleles Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004602 germ cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000037439 somatic mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28922194A | 1994-08-12 | 1994-08-12 | |
| US30026694A | 1994-09-02 | 1994-09-02 | |
| US30810494A | 1994-09-16 | 1994-09-16 | |
| US34882494A | 1994-11-29 | 1994-11-29 | |
| US40930595A | 1995-03-24 | 1995-03-24 | |
| US08/480,784 US5693473A (en) | 1994-08-12 | 1995-06-07 | Linked breast and ovarian cancer susceptibility gene |
| US08/483,553 US5709999A (en) | 1994-08-12 | 1995-06-07 | Linked breast and ovarian cancer susceptibility gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3036322T3 true GR3036322T3 (en) | 2001-11-30 |
Family
ID=27569596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20010401173T GR3036322T3 (en) | 1994-08-12 | 2001-08-06 | In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0705903B2 (el) |
| JP (1) | JP2002503943A (el) |
| CN (1) | CN1172502A (el) |
| AT (1) | ATE201445T1 (el) |
| AU (1) | AU686004B2 (el) |
| CA (1) | CA2196797C (el) |
| DE (1) | DE69521002T3 (el) |
| DK (1) | DK0705903T3 (el) |
| ES (1) | ES2158048T5 (el) |
| FI (1) | FI970513A7 (el) |
| GR (1) | GR3036322T3 (el) |
| MX (1) | MX9701075A (el) |
| NO (1) | NO970624L (el) |
| NZ (1) | NZ291621A (el) |
| PT (1) | PT705903E (el) |
| WO (1) | WO1996005306A2 (el) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995019369A1 (en) | 1994-01-14 | 1995-07-20 | Vanderbilt University | Method for detection and treatment of breast cancer |
| AU707348B2 (en) * | 1995-01-17 | 1999-07-08 | Vanderbilt University | Method for detection and treatment of breast cancer |
| US6838256B2 (en) * | 1996-02-12 | 2005-01-04 | Gene Logic Inc. | Coding sequences of the human BRCA1 gene |
| US6951721B2 (en) | 1996-02-12 | 2005-10-04 | Gene Logic Inc. | Method for determining the haplotype of a human BRCA1 gene |
| US5654155A (en) * | 1996-02-12 | 1997-08-05 | Oncormed, Inc. | Consensus sequence of the human BRCA1 gene |
| US5891857A (en) * | 1996-02-20 | 1999-04-06 | Vanderbilt University | Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins |
| AU4586697A (en) * | 1996-09-20 | 1998-04-14 | Board Of Regents, The University Of Texas System | Compositions and methods comprising bard1 and other brca1 binding proteins |
| WO1998031801A1 (en) | 1997-01-21 | 1998-07-23 | Human Genome Sciences, Inc. | I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis |
| US5965377A (en) * | 1997-03-24 | 1999-10-12 | Baystate Medical Center | Method for determining the presence of mutated BRCA protein |
| WO1998055650A1 (en) * | 1997-06-04 | 1998-12-10 | Rijksuniversiteit Te Leiden | A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination |
| US6492109B1 (en) | 1997-09-23 | 2002-12-10 | Gene Logic, Inc. | Susceptibility mutation 6495delGC of BRCA2 |
| CA2308766C (en) | 1997-11-06 | 2007-03-20 | Oklahoma Medical Research Foundation | Diagnostic assay for cancer susceptibility |
| US6177410B1 (en) | 1997-12-05 | 2001-01-23 | Vanderbilt University | Therapeutic methods for prostate cancer |
| US6686163B2 (en) | 1998-05-06 | 2004-02-03 | Gene Logic Inc. | Coding sequence haplotype of the human BRCA1 gene |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2003093261A1 (en) | 2002-04-30 | 2003-11-13 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| AU2003231293A1 (en) | 2002-05-02 | 2003-11-17 | Wyeth Holdings Corporation | Calicheamicin derivative-carrier conjugates |
| GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| ATE521341T1 (de) | 2003-12-01 | 2011-09-15 | Kudos Pharm Ltd | Dna-schäden-reparatur-hemmer zur behandlung von krebs |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| KR101138862B1 (ko) * | 2005-02-14 | 2012-05-14 | 삼성전자주식회사 | 단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법 |
| KR101206028B1 (ko) * | 2005-03-05 | 2012-11-28 | 삼성전자주식회사 | 유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이 |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| WO2007137187A2 (en) | 2006-05-18 | 2007-11-29 | Molecular Profiling Institute, Inc. | System and method for determining individualized medical intervention for a disease state |
| CA2652167A1 (en) | 2006-05-31 | 2007-12-06 | Philip Jones | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
| TWI404716B (zh) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物 |
| PL2805945T3 (pl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Indazole podstawione grupą amidową jako inhibitory polimerazy poli(adp-rybozy) - (parp) |
| MX2010002749A (es) | 2007-09-14 | 2010-06-25 | Astrazeneca Ab | Derivados de ftalazinona. |
| ES2530695T3 (es) | 2007-10-17 | 2015-03-04 | Kudos Pharm Ltd | 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluoro-bencil]-2H-ftalazin-1-ona |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| ES2466565T3 (es) | 2008-08-06 | 2014-06-10 | Biomarin Pharmaceutical Inc. | Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
| CA2737400C (en) | 2008-10-07 | 2016-11-22 | Astrazeneca Uk Limited | Pharmaceutical formulation 514 |
| CN102301002A (zh) | 2008-11-12 | 2011-12-28 | 卡里斯生命科学卢森堡控股有限责任公司 | 使用外来体来确定表现型的方法和系统 |
| WO2011007145A1 (en) | 2009-07-15 | 2011-01-20 | Astrazeneca Ab | Phthalazinone compound as parp inhibitor |
| KR20130056855A (ko) | 2010-03-01 | 2013-05-30 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 치료진단용 생물학적 지표들 |
| US9469876B2 (en) | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
| CN104789664A (zh) * | 2015-04-02 | 2015-07-22 | 安诺优达基因科技(北京)有限公司 | 用于乳腺癌易感基因BRCA1和BRCA2的Long-range PCR检测的引物组、方法及试剂盒 |
| JP6786066B2 (ja) | 2016-10-07 | 2020-11-18 | 富士通株式会社 | 家系図作成支援プログラム、家系図作成支援方法、及び家系図作成支援装置 |
| CN112566666A (zh) | 2018-05-14 | 2021-03-26 | 努瓦申生物公司 | 靶向抗癌核激素受体的化合物 |
| CN109897852A (zh) * | 2018-07-25 | 2019-06-18 | 广州普世利华科技有限公司 | 基于C2c2的肿瘤相关突变基因的gRNA、检测方法、检测试剂盒 |
| EP3969050A4 (en) | 2019-05-14 | 2023-11-01 | Nuvation Bio Inc. | COMPOUNDS TARGETING ANTI-CANCER NUCLEAR HORMONAL RECEPTORS |
| ES3021859T3 (en) | 2019-07-19 | 2025-05-27 | Astrazeneca Ab | Parp1 inhibitors |
| TW202131930A (zh) | 2019-11-13 | 2021-09-01 | 美商諾維雪碧歐公司 | 抗癌核荷爾蒙受體標靶化合物 |
| CN113388680B (zh) * | 2020-03-14 | 2023-07-04 | 复旦大学附属妇产科医院 | 上皮性卵巢癌靶点ret及其在诊断和治疗中的作用 |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| IL301921A (en) | 2020-10-09 | 2023-06-01 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| TW202304928A (zh) | 2021-03-23 | 2023-02-01 | 美商諾維雪碧歐公司 | 抗癌核荷爾蒙受體標靶化合物 |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| WO2022271547A1 (en) | 2021-06-21 | 2022-12-29 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
| WO2023089527A1 (en) | 2021-11-18 | 2023-05-25 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| MX2024007665A (es) | 2021-12-21 | 2024-07-09 | Astrazeneca Ab | Metodos de tratamiento de tumores cerebrales y neuroblastomas. |
| CN118434422A (zh) | 2021-12-28 | 2024-08-02 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和rasg12c抑制剂的组合 |
| EP4456922A1 (en) | 2021-12-28 | 2024-11-06 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atr inhibitor |
| CN118891525A (zh) | 2022-03-16 | 2024-11-01 | 阿斯利康(英国)有限公司 | 用于抗trop2抗体-药物缀合物疗法的评分方法 |
| IL316017A (en) | 2022-04-07 | 2024-11-01 | Astrazeneca Ab | Combined treatment for cancer |
| KR20240170956A (ko) | 2022-04-07 | 2024-12-05 | 아스트라제네카 아베 | 암 치료를 위한 병용 요법 |
| AU2023250030A1 (en) | 2022-04-07 | 2024-11-07 | Astrazeneca Ab | Combination therapy for treating cancer |
| KR20250023494A (ko) | 2022-06-15 | 2025-02-18 | 아스트라제네카 아베 | 암 치료를 위한 병용 요법 |
| IL318586A (en) | 2022-07-28 | 2025-03-01 | Astrazeneca Uk Ltd | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
| CN120282803A (zh) | 2022-11-30 | 2025-07-08 | 第一三共株式会社 | 抗体-药物缀合物和dnmt抑制剂的组合 |
| WO2024199668A1 (en) | 2023-03-31 | 2024-10-03 | Astrazeneca Ab | Dosing regiment of azd5305 |
| WO2025088496A1 (en) | 2023-10-24 | 2025-05-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein |
| WO2025120513A1 (en) | 2023-12-05 | 2025-06-12 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor |
| WO2025153668A1 (en) | 2024-01-19 | 2025-07-24 | Astrazeneca Ab | Pharmaceutical compositions comprising azd5305 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| CA1188246A (en) | 1981-08-31 | 1985-06-04 | Jerry L. Gregory | Immobilized microbe recycle apparatus |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4868105A (en) | 1985-12-11 | 1989-09-19 | Chiron Corporation | Solution phase nucleic acid sandwich assay |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| ES2164045T3 (es) * | 1990-06-27 | 2002-02-16 | Univ Princeton | Sondas para la deteccion de p53 mutante. |
| IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| WO1994000764A1 (en) * | 1992-06-26 | 1994-01-06 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES | The met proto-oncogene and a method for predicting breast cancer progression |
| WO1995019369A1 (en) * | 1994-01-14 | 1995-07-20 | Vanderbilt University | Method for detection and treatment of breast cancer |
| AU707348B2 (en) * | 1995-01-17 | 1999-07-08 | Vanderbilt University | Method for detection and treatment of breast cancer |
-
1995
- 1995-08-11 EP EP95305605A patent/EP0705903B2/en not_active Expired - Lifetime
- 1995-08-11 AT AT95305605T patent/ATE201445T1/de not_active IP Right Cessation
- 1995-08-11 PT PT95305605T patent/PT705903E/pt unknown
- 1995-08-11 JP JP50750796A patent/JP2002503943A/ja active Pending
- 1995-08-11 CN CN95195413.XA patent/CN1172502A/zh active Pending
- 1995-08-11 NZ NZ291621A patent/NZ291621A/en not_active IP Right Cessation
- 1995-08-11 WO PCT/US1995/010202 patent/WO1996005306A2/en not_active Application Discontinuation
- 1995-08-11 AU AU33212/95A patent/AU686004B2/en not_active Expired
- 1995-08-11 DE DE69521002T patent/DE69521002T3/de not_active Expired - Lifetime
- 1995-08-11 MX MX9701075A patent/MX9701075A/es unknown
- 1995-08-11 ES ES95305605T patent/ES2158048T5/es not_active Expired - Lifetime
- 1995-08-11 DK DK95305605T patent/DK0705903T3/da active
- 1995-08-11 CA CA002196797A patent/CA2196797C/en not_active Expired - Lifetime
-
1997
- 1997-02-07 FI FI970513A patent/FI970513A7/fi unknown
- 1997-02-11 NO NO970624A patent/NO970624L/no not_active Application Discontinuation
-
2001
- 2001-08-06 GR GR20010401173T patent/GR3036322T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ291621A (en) | 1998-09-24 |
| DE69521002D1 (de) | 2001-06-28 |
| AU686004B2 (en) | 1998-01-29 |
| ES2158048T5 (es) | 2009-11-04 |
| DE69521002T2 (de) | 2001-11-15 |
| MX9701075A (es) | 1998-03-31 |
| CN1172502A (zh) | 1998-02-04 |
| DK0705903T3 (da) | 2001-08-27 |
| WO1996005306A3 (en) | 1996-03-14 |
| NO970624D0 (no) | 1997-02-11 |
| AU3321295A (en) | 1996-03-07 |
| ATE201445T1 (de) | 2001-06-15 |
| FI970513A7 (fi) | 1997-04-07 |
| PT705903E (pt) | 2001-11-30 |
| CA2196797A1 (en) | 1996-02-22 |
| NO970624L (no) | 1997-04-14 |
| EP0705903B1 (en) | 2001-05-23 |
| DE69521002T3 (de) | 2010-02-25 |
| ES2158048T3 (es) | 2001-09-01 |
| WO1996005306A2 (en) | 1996-02-22 |
| FI970513A0 (fi) | 1997-02-07 |
| JP2002503943A (ja) | 2002-02-05 |
| EP0705903B2 (en) | 2009-08-12 |
| CA2196797C (en) | 2000-10-10 |
| EP0705903A1 (en) | 1996-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3036322T3 (en) | In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene | |
| AU3242895A (en) | 17q-linked breast and ovarian cancer susceptibility gene | |
| IL124620A0 (en) | Chromosome 13-linked breast cancer susceptibility gene | |
| EP1260520A3 (en) | Chromosome 13-linked breast cancer susceptibility gene | |
| AU7635096A (en) | Materials and methods relating to the identification and sequencing of the brca2 cancer susceptibility gene and uses thereof | |
| AU6473598A (en) | Method for determining the presence of mutated brca protein | |
| AU7459894A (en) | Polypeptides coded by exon v5 of the cd44 gene as targets for immunotherapy and immunoscintigraphy of tumours | |
| MX9701074A (es) | Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q. | |
| WO2002053018A3 (en) | Method of detecting polymorphisms associated with breast carcinoma in mhc genes | |
| GB0311835D0 (en) | Susceptibility gene for alzheimer's disease | |
| WO1999053062A3 (en) | Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof | |
| GR3023995T3 (en) | Methods of identifying lymphocytes with mutator phenotypes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ML | Lapse due to non-payment of fees |